Abbott Laboratories Corporation

Abbvie Inc.

Other

Schlumberger Technology Corporation

Arthur Gomtsyan

Erol K Bayburt

Chih-hung Lee

Robert G Schmidt

Jerome F Daanen

John R Koenig

Michael E Kort

Philip R Kym

Richard J Perner

Eric A Voight

Stanley DiDomenico

Tammie K Jinkerson

Guo Zhu Zheng

Brian S Brown

Sean Colm Turner

Gregory A Gfesser

Irene I Drizin

Margaret Chi-Ping Hsu

Phil B Cox

Michael J Dart

Anil Vasudevan

Kevin R Woller

Steven P Latshaw

Bruce Clapham

Tammie K White

Kirill A Lukin

Russell Drew Cink

Ryan G Keddy

Gilles Chambournier

Heath A McDonald

Mark A Matulenko

Marvin Robert Leanna

Dilinie P Fernando

Anurupa Shrestha

Jun Chen

Chih-Hung Lee

Stevan Wakefield Djuric

Clara I Villamil

Andrew O Stewart

Sridhar Peddi

Mikhail A Chafeev

Kristine E Frank

Kenton L Longenecker

Huaqing Liu

Derek W Nelson

Michael M Friedman

Kennan C Marsh

Justin D Dietrich

Eric C Breinlinger

Noel S Wilson

Roger J Card

Augustine Osuma

Kathleen Mortell

Robert M Leanna

Daniel P Larson

Tatyana Dekhtyar

Iok Chan Ng

M-akhteruzzaman Molla

Weili Wang

Thomas O Mitchell

Huan-Qui Li

Ann Marie Rowley

Mikhail Chafeev

Amanda W Dombrowski

Pamela S Puttfarcken

Meiqun Jiang

Sean T Turner

Richard A Perner

Phil Kym

M-Akhteruzzaman Molla

Mikhail Shafeev

Margaret Hsu

Heath A Mcdonald

Michael R Kort

Teresa Ng

Teresa (Iok Chan) Ng

Dilini Fernando

Russel D Cink

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

Tricyclic modulators of TNF signaling

This disclosure relates to: (a) compounds and salts thereof that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 

Diaminopyrimidines and uses thereof

Disclosed herein are modulators of TRPV3 of formula (I) wherein G, X, X, X, X, X, G, Z, R, R, u, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

TRPV3 modulators

Disclosed herein are modulators of TRPV3 of formula (I) wherein X, X, R, R, R, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

TRPV1 antagonists

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X, L, R, R, R, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, or combinations thereof, wherein X, X, X, X, J, K, L, X, X, R, G, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X, L, R, R, R, R, R, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G, X, X, X, X, X, G, Z, R, R, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are modulators of TRPV3 of formula (II): wherein G, X, X, X, X, X, G, R, R, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

Disclosed herein are compounds of formula (I), or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, solvates, prodrugs, salts of prodrugs, or combinations thereof, wherein R, R, R, R, and m are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

The present invention is directed to compounds of formula (I) wherein variables X, X, Y, R, R, R, R, A, A, A, and Aare as defined in the description, and methods of use to treat pain, neuropathic pain, allodynia, pain associated with inflammation or an inflammatory disease, inflammatory hyperalgesia, bladder overactivity, and urinary incontinence.

Antagonists of the vanilloid receptor subtype 1 (VR1) and uses thereof

The present invention discloses fused thienopyridyl compounds of general formula (I) wherein X-X, R-R, Zand L are as defined in the description. The resent invention also discloses a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain, urinary incontinence, bladder overactivity, and inflammatory thermal hyperalgesia in mammals, and pharmaceutical compositions including those compounds.

Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof

The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X-X, R-R, Z-Zand Arare defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.

Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Growing community of inventors

Vernon Hills, IL, United States of America

Arthur Gomtsyan